The same molecule as Ozempic and Wegovy, prepared by state-licensed 503A pharmacies under a valid prescription. 50–80% less than brand. Full pricing by dose, why it costs less, and how to vet the compounder.
Compounded semaglutide from a licensed US 503A pharmacy typically runs $200–400 per month for standard maintenance doses. That compares to $968–1,349/month for brand Ozempic or Wegovy at retail without insurance. The same active molecule, the same weekly subcutaneous injection, at roughly 70% less.
Cash price depends on weekly dose because higher doses use more API per vial. Most patients start at 0.25 mg/week and titrate up over 4–8 weeks. Maintenance is typically 1.0–2.0 mg/week. Pricing below reflects US median cash prices from state-licensed 503A compounders in May 2026.
| Weekly dose | Typical cash price | Note |
|---|---|---|
| 0.25 mg/week (starter) | $150–250/mo | Initial titration dose for the first 4 weeks. Lowest cost — least API per vial. |
| 0.5 mg/week | $200–300/mo | Standard step-up dose, weeks 5–8. |
| 1.0 mg/week | $250–350/mo | Common maintenance dose for Ozempic-equivalent therapy. |
| 2.0 mg/week | $300–450/mo | Higher maintenance dose; some prescribers use 2.4 mg to match Wegovy. |
| 2.5 mg/week (high-end) | $350–500/mo | Above-label dose; only some compounders offer this and only by prescriber request. |
Indicative prices, US national median, May 2026. Local pharmacy pricing varies. B12 / pyridoxine combinations may add $20–50/month.
Compounding pharmacies buy semaglutide API from FDA-registered foreign and domestic manufacturers, not from Novo Nordisk. The raw molecule cost is a fraction of the branded finished-dose cost.
Novo Nordisk spent ~$1.4 billion on US marketing for the GLP-1 portfolio in 2024. None of that is baked into a compounded prescription. You pay for the molecule, the pharmacy labour, and the vial — not the Super Bowl ad.
503A pharmacies prepare prescriptions per-patient under USP <797> sterility standards. Their overhead is the compounding suite, the pharmacist, and quality control — not a global supply chain.
Cash-pay compounded semaglutide skips PBMs, formularies, and rebate aggregation. The patient pays the pharmacy directly. No invisible $400 layer between you and the medicine.
The molecule is identical. Finished-product quality depends on the compounder. Look for these markers when vetting a pharmacy:
Cash pricing for compounded semaglutide varies by more than $150/month between pharmacies in the same metro area. The largest variables are pharmacy size (volume buyers get better API pricing), telehealth-clinic partnerships (clinics negotiate bulk rates), and geographic supply chain. Script Unlock surfaces real-time cash pricing from verified compounding pharmacies in your ZIP code so you can compare before you call.
Compounded semaglutide from licensed US compounding pharmacies typically costs $200 to $400 per month, depending on dose, pharmacy, and whether B12 or other additives are included. Starter doses (0.25 mg/week) run at the low end around $150–250/mo; maintenance doses (1–2 mg/week) run $250–450/mo. This compares to $968–1,349/month for brand Ozempic or Wegovy at retail without insurance. The same molecule, prepared by a state-licensed compounder, dispensed under a valid prescription.
Three structural reasons: (1) Compounding pharmacies buy bulk semaglutide API rather than finished branded product, which is dramatically cheaper. (2) None of the Novo Nordisk marketing, sales force, or executive compensation is baked into a compounded prescription. (3) Cash-pay compounded skips PBMs, formularies, and rebate aggregation — the patient pays the pharmacy directly with no middleman markup. The pharmacology is identical; the supply chain is radically simpler.
The active molecule (semaglutide) is the same. Quality of the finished product depends on the compounding pharmacy: state-licensed 503A pharmacies must follow USP <797> sterility standards, document API certificates of analysis, and pass state board inspections. 503B outsourcing facilities additionally follow cGMP and FDA inspections. Reputable compounders also conduct sterility, endotoxin, and potency testing on every batch. Ask the pharmacy for their testing protocol and state license number — a legitimate pharmacy will share both.
Yes, when dispensed by a state-licensed 503A or 503B pharmacy under a valid prescription from a US-licensed prescriber for a specific patient. FDA acknowledged Ozempic and Wegovy as in shortage from 2022, which permitted broader compounding under shortage authority; as resolutions ship, shortage-based compounding is being phased out. However, patient-specific 503A compounding remains legal when a prescriber documents clinical need that the FDA-approved drug cannot meet (e.g., custom dose, excipient sensitivity, B12 combination).
Script Unlock surfaces real-time cash pricing for compounded semaglutide from verified, state-licensed compounding pharmacies in your ZIP code. Some compounders work with telehealth weight-loss clinics; others dispense to walk-in patients with a paper or e-script. Prices vary substantially within the same metro area — the difference between the cheapest and most expensive compounder for the same dose can be $150/month or more. Avoid "research peptide" websites that bypass prescribers; those are not legal medical channels.
Verified state-licensed compounders, real-time cash pricing, no telehealth subscription required.
Search compounders